Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma Article

Omuro, Antonio, DeAngelis, Lisa M, Polley, Mei-Yin C et al. (2026). Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma . NEURO-ONCOLOGY, 10.1093/neuonc/noaf221

cited authors

  • Omuro, Antonio; DeAngelis, Lisa M; Polley, Mei-Yin C; Correa, Denise; Wefel, Jeffrey S; Bovi, Joseph A; Rosenblum, Marc; Corn, Benjamin W; Aneja, Sanjay; Grommes, Christian; Peereboom, David M; Lallana, Enrico C; Werner-Wasik, Maria; Rogers, C Leland; Iwamoto, Fabio M; Yu, Hsiang-Hsuan Michael; Donnelly, Eric D; Struve, Timothy D; Won, Minhee; Mehta, Minesh P

authors

publication date

  • January 29, 2026

published in

keywords

  • COMBINATION
  • CYTARABINE
  • Clinical Neurology
  • INTENSIVE CHEMOTHERAPY
  • Life Sciences & Biomedicine
  • METHOTREXATE
  • NERVOUS-SYSTEM LYMPHOMA
  • NON-HODGKINS-LYMPHOMA
  • Neurosciences & Neurology
  • Oncology
  • PROCARBAZINE
  • SURVIVAL
  • Science & Technology
  • THERAPY
  • VINCRISTINE
  • brain neoplasm
  • chemotherapy
  • clinical trial
  • primary central nervous system lymphoma
  • radiotherapy

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC